Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre-Antoine Bonnet

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Toxicology and Applied Pharmacology|July 26, 2005
The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizersPhilippe Azam, Jean-Luc Peiffer, Delphine Chamousset, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 8, 2017
Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in miceAdrien Chouchou, Bénédicte Marion, Christine Enjalbal, et al.
Molecules (Basel, Switzerland)|May 7, 2025
Research Progress on the Structure-activity Relationship and Mechanism of Flavonoid Derivatives in the Treatment of Lung CancerJiacheng Yao, Feng Zhu, Yikun Feng, et al.
Anti-Cancer Drugs|January 28, 2014
EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cellsJessica Saliba, Carine Deleuze-Masquéfa, Ahmad Iskandarani, et al.
International Journal of Pharmaceutical Investigation|April 26, 2018
Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503Adrien Chouchou, Anne Aubert-Pouëssel, Christophe Dorandeu, et al.
International Journal of Molecular Sciences|April 12, 2022
EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AMLHala Skayneh, Batoul Jishi, Rita Hleihel, et al.
Blood|January 26, 2008
EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphomaGeorges Moarbess, Hiba El-Hajj, Youmna Kfoury, et al.
European Journal of Medicinal Chemistry|July 28, 2017
Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitorsCindy Patinote, Nour Bou Karroum, Georges Moarbess, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|November 27, 2008
HMOX1 and NQO1 genes are upregulated in response to contact sensitizers in dendritic cells and THP-1 cell line: role of the Keap1/Nrf2 pathwayNadège Ade, Fanny Leon, Marc Pallardy, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 2, 2013
Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometryFlorian Lafaille, Isabelle Solassol, Christine Enjalbal, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Toxicology and Applied Pharmacology|July 26, 2005
The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizersPhilippe Azam, Jean-Luc Peiffer, Delphine Chamousset, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 8, 2017
Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in miceAdrien Chouchou, Bénédicte Marion, Christine Enjalbal, et al.
Molecules (Basel, Switzerland)|May 7, 2025
Research Progress on the Structure-activity Relationship and Mechanism of Flavonoid Derivatives in the Treatment of Lung CancerJiacheng Yao, Feng Zhu, Yikun Feng, et al.
Anti-Cancer Drugs|January 28, 2014
EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cellsJessica Saliba, Carine Deleuze-Masquéfa, Ahmad Iskandarani, et al.
International Journal of Pharmaceutical Investigation|April 26, 2018
Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503Adrien Chouchou, Anne Aubert-Pouëssel, Christophe Dorandeu, et al.
International Journal of Molecular Sciences|April 12, 2022
EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AMLHala Skayneh, Batoul Jishi, Rita Hleihel, et al.
Blood|January 26, 2008
EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphomaGeorges Moarbess, Hiba El-Hajj, Youmna Kfoury, et al.
European Journal of Medicinal Chemistry|July 28, 2017
Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitorsCindy Patinote, Nour Bou Karroum, Georges Moarbess, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|November 27, 2008
HMOX1 and NQO1 genes are upregulated in response to contact sensitizers in dendritic cells and THP-1 cell line: role of the Keap1/Nrf2 pathwayNadège Ade, Fanny Leon, Marc Pallardy, et al.
Journal of Pharmaceutical and Biomedical Analysis|November 2, 2013
Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometryFlorian Lafaille, Isabelle Solassol, Christine Enjalbal, et al.
Pageof 4